During a critical care rotation, a medical team is analyzing how different pharmacological… — USMLE Step 3

During a critical care rotation, a medical team is analyzing how different pharmacological interventions alter the dose-response curves of endogenous neurotransmitters or exogenous full agonists. Match each clinical drug scenario to the most accurate description of its pharmacodynamic effect on the primary agonist's dose-response curve.

Administration of naloxone to a patient receiving a continuous morphine infusionParallel rightward shift; maximal efficacy ( $E_{max}$ ) is unchanged, but apparent $ED_{50}$ increases
Treatment with phenoxybenzamine in a patient with highly elevated endogenous norepinephrineDownward shift; maximal efficacy ( $E_{max}$ ) is reduced, but apparent $ED_{50}$ remains unchanged
Initiation of buprenorphine in a patient currently dependent on high-dose oxycodoneProduces a submaximal response alone and lowers the overall maximal effect of a co-administered full agonist
Administration of midazolam in the presence of endogenous gamma-aminobutyric acidLeftward shift; apparent $ED_{50}$ decreases while maximal efficacy ( $E_{max}$ ) remains unchanged

Answer

Naloxone matches with a rightward curve shift (competitive antagonism). Phenoxybenzamine matches with a downward curve shift (irreversible non-competitive antagonism). Buprenorphine matches with producing a submaximal response and lowering a full agonist's effect (partial agonism). Midazolam matches with a leftward curve shift (positive allosteric modulation).

Each pharmacological agent possesses a unique interaction at the receptor level. Naloxone (competitive antagonist) shifts the dose-response curve to the right by increasing the apparent

ED_{50}

. Phenoxybenzamine (irreversible non-competitive antagonist) shifts the curve downward by decreasing

E_{max}

. Buprenorphine (partial agonist) plateaus at a submaximal effect and antagonizes full agonists. Midazolam (positive allosteric modulator) shifts the curve to the left by decreasing the apparent

ED_{50}

of GABA.

Step-by-Step Solution

Determine the pharmacodynamic receptor mechanism for naloxone.

Naloxone is a reversible competitive antagonist at opioid receptors.

Competitive antagonists compete for the active site but can be overcome with higher agonist concentrations, increasing

ED_{50}

without changing

E_{max}

Determine the pharmacodynamic receptor mechanism for phenoxybenzamine.

Phenoxybenzamine is an irreversible non-competitive antagonist at alpha receptors.

Irreversible binding permanently decreases the pool of available receptors, which lowers the overall

E_{max}

but leaves the

ED_{50}

of functional receptors unchanged.

Determine the pharmacodynamic receptor mechanism for buprenorphine.

Buprenorphine is a partial agonist.

Partial agonists possess submaximal intrinsic activity. When combined with a full agonist, they displace the full agonist and lower the net receptor activation, acting as functional antagonists.

Determine the pharmacodynamic receptor mechanism for midazolam.

Midazolam is a positive allosteric modulator.

Positive allosteric modulators increase the receptor's affinity for the primary endogenous ligand (GABA), meaning less ligand is required to achieve the same effect (leftward shift, decreased

ED_{50}

Key Concept

Pharmacodynamic receptor interactions and their specific effects on dose-response curve parameters (

E_{max}

and

ED_{50}

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic